Literature DB >> 8651967

Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy.

R Rivolta1, B Mascagni, V Berruti, F Quarto Di Palo, A Elli, R Scorza, D Castagnone.   

Abstract

OBJECTIVE: To evaluate the use of color-flow Doppler ultrasonography, a direct, noninvasive technique, for measurement of kidney blood flow in patients with systemic sclerosis (SSc).
METHODS: Twenty-five normal volunteers and 25 SSc patients (median disease duration 8 years, range 2-21 years) were studied. All were free of clinical symptoms of renal damage. The resistance index (RI) was determined on main, interlobar, and cortical vessels.
RESULTS: In SSc patients, the RI was significantly increased at every sampling site examined (P < 0.001). RI values were strongly correlated with disease duration (main artery r = 0.56, P < 0.04; interlobar artery r = 0.63, P < 0.02; cortical artery r = 0.75, P < 0.002). Regression analysis showed no relationship between RI and creatinine clearance values.
CONCLUSION: Color-flow Doppler ultrasonography is a sensitive and noninvasive technique for evaluating vascular damage of the kidney in patients with SSc.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651967     DOI: 10.1002/art.1780390622

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement.

Authors:  R Livi; L Teghini; A Pignone; S Generini; M Matucci-Cerinic; M Cagnoni
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

2.  Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

Authors:  Amr Amin; S El-Sayed; N Taher; M Sedki; H Nasr
Journal:  Clin Rheumatol       Date:  2012-02-24       Impact factor: 2.980

Review 3.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 4.  Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Authors:  Cosimo Bruni; Giovanna Cuomo; Francesca W Rossi; Emanuela Praino; Silvia Bellando-Randone
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

Review 5.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

6.  Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Int J Rheumatol       Date:  2010-08-17

7.  N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis.

Authors:  Edoardo Rosato; Rosario Cianci; Biagio Barbano; Ginevra Menghi; Antonietta Gigante; Carmelina Rossi; Enrico M Zardi; Antonio Amoroso; Simonetta Pisarri; Felice Salsano
Journal:  Acta Pharmacol Sin       Date:  2009-09       Impact factor: 6.150

Review 8.  Points to consider in renal involvement in systemic sclerosis.

Authors:  Felice Galluccio; Ulf Müller-Ladner; Daniel E Furst; Dinesh Khanna; Marco Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

9.  Anti-annexin v antibodies: association with vascular involvement and disease outcome in patients with systemic sclerosis.

Authors:  Reem A Habeeb; Howaida E Mansour; Aya M Abdeldayem; Rania A Abo-Shady; Iman A Hassan; Nazek K Saafan; Dalia G Aly
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2010-04-28

10.  Systemic sclerosis medications and risk of scleroderma renal crisis.

Authors:  S M Gordon; J B Hughes; R Nee; R S Stitt; W T Bailey; D J Little; J D Edison; S W Olson
Journal:  BMC Nephrol       Date:  2019-07-25       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.